Patient Responses to Cytoluminescent Therapy® for Cancer: An Investigative Report of Early Experiences and Adverse Effects of an Unconventional Form of Photodynamic Therapy

Integrative Cancer Therapies

Volumn 2, Issue 4, 2003, Pages 371-389

  Moss, Ralph W ^a  

^a Cancer Communications Inc   (United States)

Author keywords

Aftereffects; Alternative; CAM; Cancer; CLT; Complementary; Cytoluminescent; PDT; Photodynamic therapy

Indexed keywords

ACRIDINE; AMINOLEVULINIC ACID; ASCORBIC ACID; BENZOPORPHYRIN DERIVATIVE; CHLOROPHYLL; DIASPARTYLCHLORIN E6; EOSIN; FACTOR AF2; GLUTATHIONE; HEMATOPORPHYRIN; HEMATOPORPHYRIN DERIVATIVE; LUTETIUM TEXAPHYRIN; LYSYLCHLORIN P6; METHOXSALEN; MONOCHLORIN E6; OZONE; PHENACYL CHLORIDE; PHOTOFLORA; PHOTOFRIN; PHOTOSAN; PHOTOSENSITIZING AGENT; PORPHYRIN; RADACHLORIN; SILICON PHTHALOCYANINE 4; TEMOPORFIN; TETRAKIS(3 HYDROXYPHENYL)CHLORIN; THALIDOMIDE; THYMUS EXTRACT; TIN ETHYLETIOPURPURIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERTIPORFIN; XENON;

ALVEOLAR SOFT PART SARCOMA; ANOREXIA; BACKACHE; BONE METASTASIS; CANCER; CANCER MORTALITY; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL; COUGHING; CYTOLUMINESCENT THERAPY; DIARRHEA; DROWSINESS; DRUG ACCUMULATION; DRUG ACTIVATION; DRUG EXCRETION; DYSPNEA; DYSURIA; ERYTHEMA; FATIGUE; FOLLOW UP; HEADACHE; HEALTH CARE COST; HEMATURIA; HEMOPTYSIS; HISTORY; HOME CARE; HOT FLUSH; HUMAN; HYDRONEPHROSIS; ILLUMINATION; INCIDENCE; INFRARED RADIATION; INTERMETHOD COMPARISON; IRELAND; KIDNEY FAILURE; KIDNEY PAIN; LASER; LIGHT EMITTING DIODE; LIVER FAILURE; LUNG EDEMA; MUSCLE WEAKNESS; NAUSEA; NECROSIS; NERVE INJURY; NIGHT SWEAT; PAIN; PHOTOACTIVATION; PHOTODYNAMIC THERAPY; PHOTOREACTIVITY; PHOTOSENSITIVITY; PRIORITY JOURNAL; PROSTATE CANCER; PRURITUS; QUALITY OF LIFE; REVIEW; SELF CARE; SIDE EFFECT; SKIN BURNING SENSATION; SKIN CANCER; SPIRULINA PLATENSIS; THORAX PAIN; THROMBOEMBOLISM; TISSUE NECROSIS; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR GROWTH; URINARY TRACT OBSTRUCTION; URINE RETENTION; URTICARIA; VOMITING; WEIGHT REDUCTION;

ADULT; AGED; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASMS; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; TREATMENT OUTCOME;

EID: 0345688019     PISSN: 15347354     EISSN: None     Source Type: Journal    
DOI: 10.1177/1534735403259325     Document Type: Review

References (56)

1. Raab O. Über die Wirkung fluoreszierender Stoffe auf Infusorien. Z Biol (Muench). 1900;39:524-546.
2. von Tappeiner H. Über die Wirkung fluoreszierender Stoffe auf Infusorien nach Versuchen von O. Raab. Münch Med Wochenschr. 1900;47:5-7.
3. von Tappeiner H, Jesionek A. Zur Behandlung der Hautcarcinome mit fluorescierenden Stoffe. D Arch F klin Med. 1905:82, reprinted in von Tappeiner H, Jodlbauer A. Die sensibilisierende Wirkung fluoresciender Substanzen. Leipzig, Germany: Verlag von F.C.W. Vogel; 1907:72-77.
4. von Tappeiner H, Jesionek A. Zur Behandlung der Hautcarcinome mit fluorescierenden Stoffe. D Arch F klin Med. 1905:82, reprinted in von Tappeiner H, Jodlbauer A. Die sensibilisierende Wirkung fluoresciender Substanzen. Leipzig, Germany: Verlag von F.C.W. Vogel; 1907:72-77.
5. Schwartz S, Absolon K, Vemund H. Some relationships of porphyrins, X-rays and tumors. Bull Minnesota Univ School Med. 1955;27:7-13.
6. Dougherty TJ, Kaufman JE, Goldfarb A, Weishaupt KR, Boyle D, Mittleman A. Photoradiation therapy for the treatment of malignant tumors. Cancer Res. 1978;38:2628-2635.
7. Ost D. Photodynamic therapy in lung cancer: a review. Methods Mol Med. 2003;75:507-526.
8. Barr H, Kendall C, Stone N. Photodynamic therapy for esophageal cancer: a useful and realistic option. Technol Cancer Res Treat. 2003;2:65-76.
9. Kelty CJ, Marcus SL, Ackroyd R. Photodynamic therapy for Barrett's esophagus: a review. Dis Esophagus. 2002;15:137-144.
10. Karrer S, Szeimies R-M, Hohenleutner U, Landthaler M. Role of lasers and photodynamic therapy in the treatment of cutaneous malignancy. Am J Clin Dermatol. 2001;2:229-237.
11. US Food and Drug Administration. FDA oncology, tools: product label details for preparing porfimer sodium. Retrieved from www.accessdata.fda.gov/scripts/cder/onctools/ prepare.cfm?GN=porfimer%20sodium.
12. Jeffes EW. Levulan: the first approved topical photosensitizer for the treatment of actinic keratosis. J Dermatolog Treat. 2002;13:S19-23.
13. Rechtman E, Ciulla TA, Criswell MH, Pollack A, Harris A. An update on photodynamic therapy in age-related macular degeneration. Expert Opin Pharmacother. 2002;3:931-938.
14. Photosan. Retrieved July 31, 2003, from http://www.seelab. de/infopo.htm.
15. Biolitec Pharma. Foscan: summary of product statistics. Retrieved June 18, 2003, from http://www.biolitecpharma. com/public/smpc.asp?s=foscan.
16. National Institutes of Health. Clinical trials.gov. Retrieved June 18, 2003, from http://clinicaltrials.gov/.
17. Hopper C. Photodynamic therapy: a clinical reality in the treatment of cancer. Lancet Oncol. 2000;1:212-219.
18. Roberts WG, Shiau FY, Nelson JS, Smith KM, Berns MW. In vitro characterization of monoaspartyl chlorin e6 and diaspartyl chlorin e6 for photodynamic therapy. J Natl Cancer Inst. 1988;80:330-336.
19. Sessler JL, Miller RA. Texaphyrins: new drugs with diverse clinical applications in radiation and photodynamic therapy, Biochem Pharmacol. 2000;59:733-739.
20. Lim JI. Photodynamic therapy for choroidal neovascular disease: photosensitizers and clinical trials. Ophthalmol Clin North Am. 2002;15:473-478.
21. Jones HJ, Vernon DI, Brown SB. Photodynamic therapy effect of m-THPC (Foscan®) in vivo: correlation with pharmacokinetics. Br J Cancer. 2003;89:398-404.
22. Decreau R, Richard MJ, Verrando P, et al. Photodynamic activities of silicon phthalocyanines against achromic M6 melanoma cells and healthy human melanocytes and keratinocytes. J Photochem Photobiol B. 1999;48:48-56.
23. Panjehpour M, DeNovo RC, Petersen MG, et al. Photodynamic therapy using Verteporfin (benzoporphyrin derivative monoacid ring A, BPD-MA) and 630 nm laser light in canine esophagus. Lasers Surg Med. 2002;30:26-30.
24. Cox KW, Sheppard JD, Lattanzio FA, et al. Photodynamic therapy of corneal neovascularization using topical dihematoporphyrin ester. Invest Ophthalmol Vis Sci. 1997;38:S512.
25. Schuitmaker JJ, Baas P, van Leengoed HL, van der Meulen FW, Star WM, van Zandwijk N. Photodynamic therapy: a promising new modality for the treatment of cancer. J Photochem Photobiol B. 1996;34:3-12.
26. Privalov VA, Lappa AV, Seliverstov OV, et al. Clinical trials of a new chlorin photosensitizer for photodynamic therapy of malignant tumors. In: Dougherty TJ, ed. Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy XI, SPIE Proceedings. 2002;4612:178-190.
27. Photodynamic tumour therapy using Radachlorin® as photosensitizer and laser diode module mL500-SP (662 nm). Moscow; 2002.
28. Reshetnickov AV, Ponomarev GV, Ivanov AV, et al. Novel drug form of chlorin e6. In: Dougherty TJ, ed. Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy IX, SPIE Proceedings. 2000;3909:124-129.
29. Reshetnickov AV, Zalevsky ID, Kemov YuV, et al. Photosensitizer, and process therefore. RF patent no. 2183956 (priority date 3/30/2001). Assignee: RADA-PHARMA Co. Ltd., Russia. International PCT application by RADA-PHARMA Co. Ltd., Russia WO 02/078694 A12 of 10/10/02 (international priority of 10/4/01).
30. Rada-Pharma. Retrieved June 21, 2003, from www.radapharma.ru.
31. Abakumova OY, Baum RP, Ermakova NP, et al. Novel drug form of chlorin e6. In: Ivanov AV, Kazaryan MA, eds. SPIE Proceedings. 2000;4059:130-138.
32. Ivanov Av, Reshetnickov AV, Ponomarev GV. One more PDT application of chlorin e6. In: Dougherty TJ, ed. Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy IX. SPIE Proceedings. 2000;3909:131-137.
33. Uzdensky AB, Dergacheva OY, Zhavoronkova AA, Reshetnickov AV, Ponomarev GV. Photodynamic effect of novel chlorin e6 derivatives on a single nerve cell. Life Sci. In press.
34. Zimmermann A, Walt H, Haller U, Baas P, Klein SD. Effects of chlorin-mediated photodynamic therapy combined with fluoropyrimidines in vitro and in a patient. Cancer Chemother Pharmacol. 2003;51:147-154.
35. Garbo GM. Purpurins and benzochlorins as sensitizers for photodynamic therapy. J Photochem Photobiol B. 1996;34:109-116.
36. Kelly S, Kelly E. Cancer Action Plan. London: London Press; 2003.
37. CLT Clinics. Questions patients ask. Retrieved September 6, 2003, from http://www.cancerclt.com/questions.htm.
38. Kanker Actueel. Letter to the physician of Ms. Karen Kurvink. Retrieved September 6, 2003, from http://www.kanker-actueel.nl/uw_ve.Karin.html.
39. CLT Clinics. What is the cost of the treatment? Retrieved September 6, 2003, from http://www.cancerclt.com/questions. htm#question 19.
40. CLT Clinics. What are the benefits of CLT? Retrieved June 24, 2003, from cltclinics.com/frameset.html.
41. CLT Clinics. Who is not a candidate for CLT? Retrieved September 6, 2003, from http://www.cancerclt.com/questions. htm#question 19.
42. Krege S, Hinke A, Otto T, Rubben H. [Evaluation of the complementary drug Factor AF2 as a supportive agent in management of advanced urothelial carcinoma. Prospective randomized multicenter study]. Urologe A. 2002;41:164-168.
43. Singhal S, Mehta J. Thalidomide in cancer. Biomed Pharmacother. 2002;56:4-12.
44. Lynch DH, Haddad S, King VJ, Ott MJ, Straight RC, Jolles CJ. Systemic immunosuppression induced by photodynamic therapy (PDT) is adoptively transferred by macrophages. Photochem Photobiol. 1989;49:453458.
45. King DE, Jiang H, Simkin GO, Obochi MO, Levy JG, Hunt DW. Photodynamic alteration of the surface receptor expression pattern of murine splenic dendritic cells. Scand J Immunol. 1999;49:184-192.
46. Midthun DE. Endobronchial techniques in lung cancer. Options for nonsurgical care. Postgrad Med. 1997;101:169-172, 177-178.
47. Friedberg JS, Mick R, Stevenson J, et al. A phase I study of Foscan-mediated photodynamic therapy and surgery in patients with mesothelioma. Ann Thorac Surg. 2003;75:952-959.
48. Gollnick SO, Evans SS, Baumann H, et al. Role of cytokines in photodynamic therapy-induced local and systemic inflammation. Br J Cancer. 2003;88:1772-1779.
49. Kick G, Messer G, Goetz A, Plewig G, Kind P. Photodynamic therapy induces expression of interleukin 6 by activation of AP-1 but not NF-kappa B DNA binding. Cancer Res. 1995; 55:2373-2379.
50. Roswell Park Cancer Institute. Photodynamic Therapy (PDT) Center. Retrieved September 6, 2003, from http:///www. roswellpark.org/document_1153_266.html.
51. Tisdale MJ. The "cancer cachectic factor." Support Care Cancer. 2003;11:73-78.
52. Dr. Donsbach's Healthcare Products. Retrieved September 7, 2003, from http://www.donsbach.com/products/male.htm.
53. Marks LS, DiPaola RS, Nelson P, et al. PC-SPES: herbal formulation for prostate cancer. Urology. 2002;60:369-375, 376-377.
54. Matthews SJ, McCoy C. Thalidomide: a review of approved and investigational uses. Clin Ther. 2003;25:342-395.
55. Kirkwood J. Cancer immunotherapy: the interferon-alpha experience. Semin Oncol. 2002;29(3S7):18-26.
56. CLT Clinics. How will I know I am receiving authentic CLT? Retrieved September 6, 2003, from http://www.cancerclt. com/questions.htm#question13.